Amyotrophic lateral sclerosis and frontotemporal dementia are two neurodegenerative diseases with currently no cure. These two diseases share a clinical continuum with overlapping genetic causes. Mutations in the CHMP2B gene are found in patients with ALS, FTD and ALS-FTD. To highlight deregulated mechanisms occurring in ALS-FTD linked to the CHMP2B gene, we performed a whole transcriptomic study on lumbar spinal cord from CHMP2B intron5 mice, a model that develops progressive motor alterations associated with dementia symptoms reminiscent of both ALS and FTD. To gain insight into the transcriptomic changes taking place during disease progression this study was performed at three stages: asymptomatic, symptomatic and end stage. We showed that before appearance of motor symptoms, the major disrupted mechanisms were linked with the immune system/inflammatory response and lipid metabolism. These processes were progressively replaced by alterations of neuronal electric activity as motor symptoms appeared, alterations that could lead to motor neuron dysfunction.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS), the most common adult-onset motor neuron disease, is characterized by the degeneration of motor neurons associated with progressive muscle denervation and atrophy leading to paralysis and death usually within two to five years following diagnosis (Hand and Rouleau, 2002) . Frontotemporal dementia (FTD) is the second most common cause of dementia in people under the age of 65 years after Alzheimer's disease (Ratnavalli et al., 2002) . It mainly affects anterior temporal and/or frontal lobes of the brain, causing progressive degeneration of the frontal and temporal cortical neurons and subsequent dementia (Pressman and Miller, 2014) .
Although selective groups of neurons are primarily affected in each disease (Lillo and Hodges, 2009 ) increasing evidence suggests that ALS and FTD may fall into the same disease spectrum Gao, 2014, Ling et al., 2013) . ALS and FTD share common pathophysiological features with overlapping genetic causes. Approximately 15-20% of ALS patients present with cognitive impairment reminiscent of FTD and approximately 15% of FTD patients develop ALS (Lillo and Hodges, 2009, Phukan et al., 2012) . Therefore, ALS and FTD are now considered overlapping clinical syndromes with common causes.
Understanding the common mechanisms and biochemical pathways driving the neurodegenerative processes in these diseases is essential to delineate new therapeutic strategies that could be used for the diseases belonging to this continuum.
Among the genes associated with these two diseases, mutations in the CHMP2B (Charged Multivesicular Body protein 2B) gene, although rare, are found in patients with ALS ( Parkinson et al., 2006 , Cox et al., 2010 , Van Blitterswijk et al., 2012 analysis on forebrain-type cortical neurons derived from human induced pluripotent stem cells obtained from patients carrying the 31449G > C mutation (Zhang et al., 2017) . This mutation generates a G to C transition in the 5' acceptor splice site of exon 6, producing two aberrant transcripts: CHMP2B intron5 and CHMP2B ∆10 leading to a troncation of 36 amino acids at the C-terminal part of the protein. Interestingly, this deleted region contains point mutation sites found in ALS (Cox et al., 2010) and FTD (Ghanim et al., 2010) patients, suggesting a common contribution of this region to both pathologies. In addition to misregulation of genes related to endolysosomal pathway, mitochondria and oxidative stress, this study brought to light an alteration of genes involved in iron homeostasis that may trigger mitochondrial alterations, ROS production and neuronal damages. Although giving important informations about the mechanisms activated by CHMP2B mutants, these two studies present some limitations. Indeed, in both cases, the alteration of genomic profiles found are cell-type specific. Thus the obtained results can neither reflect the global changes at a whole tissue level with complex cell-cell interactions, nor the changes of genomic profiles associated with disease progression.
We have previously shown in transgenic mice that CHMP2B intron5 mutant specifically expressed in neurons using the Thy1.2 promoter triggers a progressive age-dependent motor phenotype associated with behavioral changes that recapitulate ALS and FTD disorders (Vernay et al., 2016) . In an attempt to better understand the mechanisms linking CHMP2B intron5 to ALS in this model and to investigate the impact of CHMP2B intron5 neuronal expression in a global context we performed a transcriptomic analysis based on RNAsequencing on lumbar spinal cord of this transgenic CHMP2B intron5 mouse model. To gain access to the changes associated with disease progression, gene profiling was performed at three time-points corresponding to asymptomatic, symptomatic and end stage of the disease.
In a second step, in an attempt to investigate overlapping alterations in gene expression between two ALS-causing genes, we compared the transcriptome of symptomatic CHMP2B intron5 mice with the one of symptomatic SOD1 G86R mice previously published by our laboratory (Henriques et al., 2017) .
MATERIAL AND METHODS
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Animals
Homozygous CHMP2B intron5 transgenic mice overexpressing the human CHMP2B intron5 mutant under the Thy1.2 promoter were obtained by breeding hemizygous mice carrying 6 copies of the transgene (mixed FVB/N-DBA/2-C57BL/6 background) and were genotyped as previously described (Vernay et al., 2016) . Male homozygous mice carrying 12 copies of the transgene (Tg) were used in this study and compared with control non-transgenic (nTg) littermates. Transgenic mice overexpressing murine SOD1 with the G86R mutation were genotyped as previously described (Ripps et al., 1995) .
Mice were group-housed (2-5 per cage) in the animal facility of the medicine faculty of Strasbourg University, in a temperature-and humidity-controlled environment at 22±1 °C under a 12-h light/dark cycle with unrestricted access to regular A04 rodent chow and water. CHMP2B Intron5 mice were studied at three pre-defined stages of disease progression: at 1.5 month of age, an asymptomatic (AS) stage when motor symptoms are absent; at 6 months of age corresponding to the symptomatic (S) stage of the disease when mice develop signs of hindlimb weakness; and at 10-12 months of age corresponding to the end (E) stage of the disease when mice display hindlimb paralysis or loss of the righting reflex. SOD1 G86R mice were studied at 90 days corresponding to the S stage of the disease when mice develop signs of hindlimb weakness. At the selected time points, mice were sacrificed by lethal injection of pentobarbital (120mg/kg IP). Tissues were carefully dissected, snap-frozen in liquid nitrogen and stored at -80° or fixed by immersion in paraformaldehyde 4% in 0.1M phosphate buffer
Pathway analysis
Gene enrichment analysis was performed by using Gene Ontology and Consensus Pathway Data Base. For theses analyses of the CHMP2B intron5 mice, genes with an adjusted p-value lower than 0.05 and a fold change (FC) value <0.67 for down-regulated or >1.5 for upregulated genes were selected. Pathway over-representation composed of at least 3 genes and with an adjusted p-value<0.05 was considered as significantly altered.
Statistical analysis
Unless otherwise indicated, data are expressed as the mean ± SEM. GraphPad Prism version 6.0a software was used for statistical analysis. Tests used are indicated in the legends under the figures. Differences with p-values <0.05 were considered significant. The statistical significance of the overlap between the lists of significantly differentially expressed genes in CHMP2B intron5 and SOD1 mice was computed using an hypergeometric test.
RESULTS
Deregulated genes in the spinal cord of CHMP2B intron5 mice: transcriptomic analysis discriminate between CHMP2B intron5 Tg mice and nTg mice at the three stages of the disease.
To gain insight into the nature and extent of gene expression changes occurring in ALS-FTD syndrome linked to CHMP2B intron5 mutation in mice, the spinal cord transcriptomes of Tg and age-matched nTg mice were studied by RNA-sequencing at three stages of disease progression: AS stage (1.5 month of age, no motor symptom) S stage (6 months of age, signs of hindlimb weakness) and the E stage of the disease (10-12 months of age, hindlimb paralysis or loss of the righting reflex).
Principal component analysis (PCA) performed with the ~34000 expressed genes for each stage showed a clear discrimination between genotypes at AS and E stages. This segregation was less pronounced at S stage probably reflecting an heterogeneity of disease progression between Tg mice ( Figure 1 ). Indeed, S stage represents an intermediate situation where all mice are not necessarily at the same stage of disease development even if hindlimb weakness is seen. To improve the analysis, we then selected the deregulated genes with an adjusted p-J o u r n a l P r e -p r o o f value <0.05. As shown in table 1 the number of deregulated genes with an adjusted p-value <0.05 increased with disease progression. Using this first cut-off, unsupervised hierarchical clustering showed that these differentially expressed genes segregated all the Tg mice from their nTg littermates as shown by the dendrograms in Figure 2A . To highlight the most altered cellular processes, a fold change (FC) value <0.67 for down-regulated or >1.5 for upregulated genes and an adjusted p-value <0.05 were used as criteria for defining a set of deregulated candidate genes in Tg when compared to nTg mice. Comparison of gene expression resulted in 281, 576 and 348 differentially regulated genes at the AS, S and E stage respectively (Table 1) . Interestingly, as disease progressed, the percentage of up-regulated genes in Tg mice was decreased while the percentage of down-regulated genes was increased when compared to nTg littermates ( Figure 2B ). Complete lists of genes found either up-or down-regulated in Tg when compared to nTg mice are given in supplementary tables 2-4.
Among the deregulated genes identified, 49 were common to the three time points with 19 upregulated and 30 repressed ( Figure 2C ).
To ascertain RNA-sequencing results, gene expression was then assessed by RT-qPCR on an independent cohort of mice. For each stage, 10 genes were selected on the basis of their FC.
Expression levels of the selected transcripts obtained by RT-qPCR were comparable with the FC found by RNA-seq analysis except for 3 genes, Hsd11b1 at AS stage and Unc13 (p=0.079) and Flnc at ES stage whose regulation did not reach significance ( Figure 3 ).
Transcriptomic profiles evolve as disease progresses
In an attempt to identify the mechanisms altered throughout the course of the disease and the pathways with a significant number of differentially expressed genes, gene ontology analysis was performed with significantly dysregulated genes.
At the AS stage, while no evident histological changes are found in the spinal cord (supplementary figure 1), two major pathways emerged as over-represented: the immune system (34% of the deregulated genes; over-representation: p adj =2.1e-14) and the metabolism of lipids (9.6% of the deregulated genes, over-representation: p adj =1.10e-03). Among the 95 (FC>1.5) and its receptor C3ar1 (FC=2.01), and other receptors (Fcer1g, Fcgr1, Csf1r, Ptafr and Tlr2) .
In addition, we showed an increase of Trem2 (FC=3.1) a type I transmembrane protein primarily expressed in microglia in the central nervous system and of its protein adaptor Tyrobp (FC=2.42), as well as of other lectin-related inflammatory proteins such as Lgals3 (FC=3.39), Clec7a (FC=3.06) and the integrin Itgax (FC=5).
The second pathway identified as over-represented dealt with the metabolism of lipids (Table   3 ), a pathway known to be altered in ALS (Dupuis et al., 2008) . Indeed, amongst the 281 deregulated genes, 27 genes belong to the lipid metabolism process with 13 genes downregulated and 14 genes up-regulated. These deregulated genes were involved in plasma lipoprotein assembly, remodeling, and clearance, cholesterol metabolism, synthesis of very long-chain fatty acyl-CoAs and steroids metabolism (Table 3) .
Six lipases were deregulated: 60kDa lysophospholipase (Aspg: FC=2.19), lipoprotein lipase (Lpl: FC1.9), phospholipase D4 (Pld4: FC=1.73), phospholipase B1 (Plb1: FC=1.53) endothelial lipase (Lipg: FC0.64) and phospholipase A2 (Pla2g3: FC=0.58).
The two apolipoproteins Apoc1 and Apoe were up-regulated with a FC of respectively 2.34 and 1.75 while cubilin (Cubn) a protein that mediates high density lipoproteins transport was down-regulated (FC=0.65).
In addition, three enzymes involved in the metabolism of sphingolipids were down regulated: the serine palmitoyltransferase small subunit B (Sptssb: FC= 0.62), a subunit of serine palmitoyltranferase that catalyzes the first step in the biosynthesis of sphingolipids, the sphingosine-1-phosphate phosphatase 2 (Sgpp2: FC=0.65) responsible of sphingosine-1phosphate synthesis and the 2-hydroxyacylsphingosine 1-beta-galactosyltransferase (Utg8a: FC=0.65) which catalyzes the synthesis of galactosylceramide from ceramide. Finally, Hexb, the beta subunit of hexosaminidase that converts ganglioside GM2 to GM3 was overexpressed (FC=1.52). Four genes involved in steroid metabolism were down-regulated: the corticosteroid 11-beta-dehydrogenase isozyme 1 (Hsd11b1: FC=0.55) which converts cortisone into corticosterone, 3-alpha-hydroxysteroid dehydrogenase type 1 (Akr1c4: At the S stage (Table 4) , when motor impairments are obvious, the mainly altered processes were related to neuronal system/activity. Indeed, 43 genes associated with this process were deregulated (7.4% of the deregulated genes; over-representation: p adj =6.3e-6). Most of them were related to electrical activity of the neuron including potassium and sodium channels, neurotransmitter receptors or transporters and axon guidance. Potassium channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. They play a crucial role in maintaining membrane potential and modulating electrical excitability in neurons. Thirteen potassium channel subunits or potassium channelrelated genes were deregulated. Kcnh4, Kcnj4, Kcnmb1, Kcns1, Kcnv1 and Hcn3 and Gnb3 mRNAs were up-regulated while Kcna1, Kcna2 Kcnc3, Kcng4, Hcn2 and Abcc9 mRNAs were repressed. Sodium channels expression was also altered. Voltage-gated sodium channels subunits alpha Scn9a, Scn10a, Scn11a and nicotinic receptor subunits Chrna6 and Chrnb3 mRNAs were up-regulated. In contrast voltage-gated sodium channel ß subunit Scn4b and nicotinic receptor alpha2 subunit Chrna2 mRNAs were repressed. In addition sodium-coupled neurotransmitter transporters were also identified. Slc17a7 encoding the vesicular glutamate transporter VGLUT1 and Slc6a12 encoding the GABA transporter GAT2 were up-regulated.
At the same time, Slc6a4 encoding the serotonin transporter SERT and Slc6a5 encoding the glycine transporter GLYT2 were repressed. In addition, Slc1a2 (FC=0.72, not included in table 3), encoding the glutamate transporter EAAT2 was also repressed but does not reached our FC threshold. Finally, mRNAs encoding GABA receptor rho2 subunit Gabrr2 was up regulated while GABA receptor ß2 subunit Gabrb2 and glycine receptor 1 subunit Glra1 were down regulated in Tg when compared to nTg mice.
At E stage deregulation of neuronal system (4.3% of the deregulated genes, overrepresentation: p adj =0.038) was still present (Table 5 ). However, the number of deregulated genes was decreased when compared to S stage falling from 43 to 15 genes. Potassium channels family remained the most represented family with 6 out of 15 genes identified. In addition to the neuronal system, a new pathway linked with extracellular matrix emerged (Table 6 ). In this pathway mRNAs encoding collagens (Col6a, Col9a3, Col20a1 and Col 27a1) were up-regulated while mRNAs encoding integrins were either up-(Itgad, Itgax) or down-regulated (Itga1, Itgb3) and proteoglycans Acan and Hapln were down-regulated.
J o u r n a l P r e -p r o o f
In independent control experiments, mRNA levels of neuronal markers were measured by RT-qPCR in order to determine whether the effects seen on the above mentioned neuronal genes were due to a neuronal loss. As shown on supplementary figure 2 expression levels of the 7 different neuronal genes tested were unchanged in Tg compared to nTg mice. The absence of obvious neuronal loss was confirmed by NeuN immunostaining.
To complete our analyses, we studied the progression of genes expression from the overrepresented families. We studied the profile of each gene and classified the genes according to their expression level as compared to nTg mice, throughout the course of the disease. For each family and each stage, the number of deregulated genes and the corresponding percentage of genes either up-or down-regulated or with an unchanged expression are summarized in table 7 and the full list of genes is given in supplementary table 5. As shown in figure 4, for the families that were over-represented at the AS stage, an expression pattern showing an initial up-regulation of this group of genes before returning to an expression level comparable to nTg mice largely prevailed. Indeed, 71% and 33% of the genes for the immune system/inflammation and lipid metabolism respectively showed this pattern of expression.
Interestingly, in both families the percentage of over-expressed genes at AS was strongly decreased at S stage (less than 10%) but re-increased up to 16.8% and 18.5% in both family at the E stage. In contrast, if the percentage of down-regulated genes was stable (3%) at the S and E stage for the immune system, it represented around 22% of the genes of the lipid metabolism family initially found deregulated. For the genes belonging to the neuronal system that were over-represented at S stage, the expression pattern that prevailed (~40% of the genes) showed an up-regulation limited to this stage with a normal level of expression at AS and E stages. The deregulated genes represented ~15% and ~35% of the family at the AS and E stages with a majority of repressed genes. For the two over-represented families at the E stage a common expression pattern prevailed with a normal expression level at the AS and S stages followed by an up-regulation at the E stage. These genes represented ~27% and ~46 % of the deregulated genes for the neuronal system and the ECM respectively. For the neuronal system, a second pattern corresponding to a normal level of expression at the A stage followed by a down regulation at the S and E stages was seen for ~27% of the genes. The percentage of up-regulated genes increased progressively from AS (~7%) to E stage (~47%) while the percentage of repressed genes was stable at AS and S stages (~13%) and was increased by 4-folds at E stage. For the ECM family, the percentage of up-regulated genes J o u r n a l P r e -p r o o f was stable at AS and S stages (~8%) and was increased by 8-folds at E stage while the percentage of repressed genes increased progressively from AS (~15%) to E stage (~38%).
Finally, in these over-represented families, 8 genes were constantly up-regulated while 12 were constantly down-regulated (supplementary table 5).
In order to further determine the genes that were constantly deregulated during disease progression, irrespective of the over-represented families, we compared the deregulated genes at the three stages. Forty-nine genes common to AS, S and E stages were found (Table 8) .
Twelve genes were related to the neuronal system (Chrna2, Hspb1, Kcnc3, Kcnh4, Nnat, Pdlim4, Scn4b, Slc6a5, Sspo, Steap2, Strip1, Uts2) , 5 were linked to lipid metabolism (Apoc1, Gpd1, Hsd11b1, Sptssb, Ugt8a), 4 were linked to the immune system (C4a, C4b, Lgals3, Thy1) and 2 were related to ECM (Acan, Hapln1). In addition, a new category related to transcription became apparent with the induction of the transcriptional regulators Atf3, Batf3, Prrx2 and Wisp2 and the down-regulation of histone methyl transferase Smyd1. Interestingly all the identified genes were either up-or down-regulated over the three stages. Amongst the repressed genes, 11 were of unknown function.
CHMP2B intron5 and SOD1 G86R mice share common deregulated genes at symptomatic stage of the disease
In an attempt to investigate overlapping alterations in gene expression profiles and highlight pathological mechanisms common to two ALS-related mutants, we compared our results obtained on spinal cord from CHMP2B intron5 mice at S stage with those of transcriptomic analyses performed on spinal cord from SOD1 G86R mice at 90 days of age corresponding to the S stage, when mice develop signs of hindlimb weakness in this line. Using the same criteria than those used for CHMP2B intron5 model analysis, we found 449 deregulated genes in SOD1 G86R mice when compared to controls. Among them, 28 were common to both models, with 22 genes up-regulated, 3 genes down-regulated and 3 genes with opposite deregulations.
The overlap between the lists of differentially expressed genes in CHMP2B intron5 and SOD1 G86R mice was statistically significant (p-value=2.770336e-08, hypergeometric test). We then categorized these genes and identified 7 deregulated processes (see Table 9 for details). The most represented was the immune system including inflammatory response, followed by molecules involved in transcription, lipid metabolism, neuronal system, repression of translation and cell-cell interactions. Two genes were of unknown function. This model that develops characteristic features of ALS at the motor and histological levels is based on the neuronal over-expression of the CHMP2B intron5 mutant (Vernay et al., 2016) .
Using RNAseq followed by bioinformatic analysis we established that as early as 1.5 month of age, the transcriptomic profiles of CHMP2B intron5 Tg mice showed their own gene expression signature that differs from nTg mice. This demonstrates that transcriptomic changes, confirmed by RT-qPCR on an independent cohort, already exist several weeks before the first visible clinical motor symptoms. In this transgenic line, CHMP2B intron5 expression is driven by the Thy1.2 promoter, a promoter known to be neuron specific with a strong expression in motor and cortical neurons (Gordon et al.,1987) . In Thy1.2-CRE transgenic mice, expression starts from E11 to E14 in the cortex depending on the transgenic line (Campsal et al., 2002) . In Tg mice we found a cortical expression of the CHMP2B intron5 mutant concomitant with the expression of endogenous CHMP2B at the mRNA levels as early as E15 (data not shown). This early expression of the transgene concomitant with endogenous CHMP2B suggests a potential effect of the mutant protein early in the course of development as it could happen in patients carrying the mutant gene. This transcriptomic profile of over-represented families amongst the deregulated genes evolves through the course of the disease with a progressive switch of deregulated pathways from immune system/inflammatory response and lipid metabolism to neuronal system and ECM when motor symptoms become visible.
Neuronal expression of CHMP2B intron5 triggers an initial inflammation with disruption of lipid metabolism before onset of motor symptoms.
Inflammatory processes are strongly related to ALS and FTD but also to other neurodegenerative disorders such as Alzheimer or Parkinson diseases. Their role in the development and progression of neurodegenerative diseases is however not clearly understood. Here, we report that neuronal expression of CHMP2B intron5 mutant triggers a J o u r n a l P r e -p r o o f strong activation of immune system associated with an activation of the inflammatory response in spinal cord before any motor symptoms. Indeed, transcripts encoding chemoattractant proteins CCL3, CCL4 and CCL6 that stimulate the recruitment of inflammatory cells (Schulthess et al., 2012) are induced together with an increase of microglial/macrophage or astrocyte markers (Aif1/Iba1; Cx3cr1; Cd68; Cd14; Cd52; Gfap).
In addition expression of IL-1α and TNF receptors, which are related to the proinflammatory pathway (Tortarolo et al., 2015) , and complement cascade components are also up-regulated. These data are in agreement with the data obtained in another transgenic mouse line over-expressing CHMP2B intron5 under the prp promoter and in human CHMP2B mutation carriers. Indeed, Isaac's group demonstrated the presence of an early microgliosis in brain of CHMP2B intron5 mice with an up-regulation of mRNAs encoding inflammation markers including Irf8 and Csf1r two genes overexpressed in our study (Clayton et al., 2017) .
Interestingly, in human CHMP2B mutation carriers, it was recently shown that serum levels of CCL4 are increased throughout life (Roos et al., 2018) . In sporadic ALS patients CCL3, CCL4, IL-1 are increased in CSF while TNF receptor levels are increased in plasma. In addition CCL6 is over-expressed in astrocytes from SOD1 G37R mouse model (Sun et al., 2015) and activation of complement cascade is also observed in SOD1 G93A mouse model (Ferraiuolo et al., 2007) and in serum of ALS patients (Apostolski et al., 1991) . However, depletion of C1q or C3, two essential proteins of complement cascade, does not increase the lifespan of SOD1 G37R nor delay the degeneration of motor neurons (Lobsiger et al., 2013) suggesting that complement activation is a consequence rather than a cause of disease progression. We also highlight the activation of an inflammatory pathway based on TREM2. TREM2 was previously associated with both ALS pathogenesis (Cady et al., 2014) and microglial activation (Cantoni et al., 2015) and very recently with FTD caused by CHMP2B mutants (Roos et al., 2018) . TREM2 is a cell surface receptor expressed by microglia, interacting with protein tyrosine kinase binding protein (TYROBP). This apoptotic cell-detector which recognizes a variety of ligands, is able to bind Apolipoprotein E (ApoE) (Bailey et al., 2015) and to promote proinflammatory mechanisms by the induction of inflammatory players (Krasemann et al., 2017) . Interestingly, using microarray analysis, Cox and collaborators found that ApoE is over-expressed in motoneurons of human CHMP2B mutation carriers (Cox et al., 2010) . Our results show the induction of Trem2 and its interactor Tyrobp associated with an induction of Apoe and inflammatory markers including Clec7a, Lgals3, Gpnmb and Itgax. Interestingly, Clec7a is also over-expressed in astrocytes of SOD1 G93A ALS mouse model (Baker et al., 2015) while Itgax and ApoE are increased in microglia (Chiu et J o u r n a l P r e -p r o o f al., 2013). However, the exact consequence of TREM2 pathway activation is currently still a matter of debate. Indeed, recent data suggest a rather beneficial neuroprotective role of TREM2 by interacting with TLR2 and CD14, two genes that are both shown to be induced in the present study. Thus, whether TREM2 pathway activation is beneficial or deleterious in the pathological context linked to CHMP2B intron5 neuronal expression remains to be elucidated.
Lipids directly contribute to cell signaling, membrane stability/fluidity and neuronal energy balance during stress. It was recently shown that hyperlipidemia is a causal risk factor in ALS patients (Bandres-Ciga et al., 2019) . Some recent lipidomic studies point towards a change in lipid metabolism in ALS-FTD patients characterized by an increase of circulating triglycerides level and cholesterol/HDL ratio, and a decrease of LDL and APOC1 . However little is known about human CHMP2B mutation carriers. Here, we show for the first time that early in the course of the disease, before any motor symptoms, that expression of genes implicated in the lipid metabolism are significantly altered in CHMP2B intron5 Tg mice. Indeed, expression of several genes encoding proteins involved in plasma lipoprotein formation and clearance, cholesterol metabolism, synthesis of very long chain fatty acids and steroid metabolism is altered. Apoe expression is increased as previously found in a transcriptomic analysis of motor neurons from human CHMP2B mutation carriers (Cox et al., 2010) . However, in an experimental cellular model (IPSC-derived cortical neurons expressing CHMP2B mutant) an opposite result was obtained suggesting a potential importance of culture manipulations and conditions or the limits of such models (Zhang et al., 2017) . Lipidation of APOE can be performed by ABCA1 a membrane receptor mainly found in the plasma membrane of astrocytes that mediates the efflux of cholesterol and phospholipids to lipid-poor apolipoproteins (Wahrle et al., 2004) . In the present transcriptomic analysis Abca1 expression is also found to be induced (FC=1.41) although not reaching the chosen threshold of significance. Nevertheless, this increase of Abca1 could favor the transport of lipids by APOE to neurons and glia. Associated with these up-regulations of lipids import factors, LPL which hydrolyzes and transports free fatty-acids to neurons and schwann cells Robbins, 1984, Huey et al., 1998) is also induced suggesting an increase of lipids availability for these cells. Of note, gene expression profiling and proteomic analyses reported increased levels of LPL in mutant SOD1 G93A mouse spinal cords. However, in our study other deregulations point toward an inhibition of lipids uptake. The decreased expression of enzymes involved in the synthesis of cholesterol and very long chain fatty acids (Hmgcs1, Idi1, Tecrl, Elovl2) could lead to a global reduction of lipids bioavailability. Hmgcs1 was found down regulated in a transcriptomic study performed on spinal cords from ALS patients (D'Erchia et al., 2017) . We further observed a decrease of Cubn which is involved in the endocytosis of holoparticles of HDL (Hammad et al., 1999) .
Finally, sphingolipids are involved in key pathways for ALS, such as autophagy and protein clearance, cell survival, energy metabolism, and neuroinflammation. Our analysis also identified two genes whose deregulation would deregulate the glycosphingolipid pathway:
Ugt8a and Hexb. Interestingly, similar regulations were found in SOD1 G86R mice, and Ugt8a expression level correlated with disease severity (Henriques et al., 2017) . All these alterations in lipid metabolism may affect the cell metabolism and the organization of cellular membranes and, in turn, modify axon guidance and synaptic transmission participating to disease progression and neuronal dysfunction.
In the CHMP2B intron5 mice, at the early stage of the disease, deregulation of the immune system and lipid metabolism are concomitant. Numerous data have already shown that these two processes can be linked by oxidative stress. Indeed, activated microglial cells increase ROS production (Haslund-Vinding et al., 2017, Peterson and Flood, 2012) leading to oxidation of lipids in the plasma membranes of the surrounding cells (de la Haba et al., 2013 , Yang et al., 2006 . This oxidation of membrane lipids promotes membrane curve disturbance and favors aggregates formation. Moreover, changes in composition of membrane lipids are also known to alter synaptic plasticity and trigger apoptosis (Ledesma et al., 2012) . Cutler showed that oxidative stress leads to an increase of ceramide and cholesterol in ALS patients and that inhibition of ceramide and cholesterol synthesis protects against cell death induced by oxidative stress (Cutler et al., 2002) . On the other hand, specific class of lipids such as prostaglandins or platelet activating factor (PAF) can also trigger inflammation. In our study, we observed an increased expression of Plb1 that encodes an enzyme involved in the metabolism of glycerophosphocholine, a precursor of PAF (Edwards and Constantinescu, 2009, Marrache et al., 2002) . In addition, Ptafr, encoding the PAF receptor expressed on cell surface of microglia (Aihara et al., 2000) is also over-expressed in our transgenic mice suggesting an activation of the PAF pathway.
J o u r n a l P r e -p r o o f
Altogether, the results obtained at the asymptomatic stage suggest that activation of the immune system represents the initial step of disease onset. One possible cause could be the abnormal accumulation of protein aggregates due to neuronal expression of CHMP2B intron5 that are already detectable at this stage and may trigger the inflammatory response, which then could further participate to neurotoxicity and disease progression. However, activation of immune system and inflammation is not specific to CHMP2B intron5 mutant and seems to be a general mechanism in ALS, irrespective of the initial cause of the disease, similar activation being also found in sporadic ALS and FTD patients (McCauley and Baloh, 2018 , Prado et al., 2018 , Roos et al., 2018 . The hypothesis of aggregate-causing inflammation has already been proposed for other neurodegenerative diseases and will be explored in the near future in this model. At this stage, the metabolism of lipid is also impacted by CHMP2B intron5 neuronal expression. The emerging question is: which process impacts the other? Does the inflammatory response lead to the perturbation of lipid metabolism observed in ALS patients (Schmitt et al., 2014) or the reverse? Another hypothesis could be that proinflammation and lipid metabolism impairment are associated to generate a neurotoxic environment leading to neuronal dysfunction and neuronal death. As recalled above, oxidative stress could be the possible link between inflammation and lipid metabolism.
At the symptomatic and end stages, neuronal functions are deregulated
One of the characteristic features of ALS is the presence of muscle fasciculations. The origin of fasciculations depends on the functional state of lower motor neurons and is associated with an increase of their excitability .
A precise balance between neuronal excitation and inhibition is crucial for proper functioning of the nervous system. Disturbance of neuronal excitation-inhibition homeostasis results in severe pathological phenotypes, such as excitotoxic neurodegeneration, epilepsy, muscular spasticity, and mental retardation (Zoghbi et al., 2000) . Electrical activity of the neuron and excitability are tightly link to the nature of ion channels expressed by the neuron. This homeostasis relies on the expression of ion channels, neurotransmitter receptors and transporters. So far the only study linking CHMP2B mutant to an alteration of neuronal functionality showed that mutant CHMP2B elicits a decrease in synaptic activity and suggest that the pathogenic proteins may perturb synaptic plasticity and microstructure, long before overt cell death (Belly et al., 2010) . In this study, at symptomatic stage when motor symptoms J o u r n a l P r e -p r o o f are present in the CHMP2B intron5 mice, we highlighted a major deregulation of genes implicated in the electrical activity of the neurons (i.e. potassium and sodium channels, neurotransmitter receptors and transporters) potentially leading to a hyperexcitability of the neurons. In support of this hypothesis Kcna1 and Kcna2, that encode Kv1.1 and Kv1.2 alpha subunits voltage-gated potassium channels involved in repolarization and hyperpolarization of neurons by efflux of potassium ions, are down-regulated. Kcna1 knock-out leads to a hyperexcitability of neurons with a lower excitation threshold without any change in resting potential (Brew et al., 2003) and mice develop seizures (Rho et al., 1999) . In ALS patients Kcna1 and Kcna2 expression is decreased and correlates with hyperexcitability (Kanai et al., 2006 , Kleine et al., 2008 , Vucic and Kiernan, 2006 , supporting the involvement of these two channels in the disease. In addition, Scn10a encodes Nav1.8 alpha subunit of a voltage-gated sodium channel that supports repetitive firing in response to sustained depolarization is increased, and gain-of-function mutations of Nav1.8 produce neurons hyperexcitability suggesting that over-expression of Scn10a could lead to hyperexcitability (Han et al., 2016) .
Interestingly, Scn11a that encodes the Nav1.9 voltage-gated sodium channel contributing to persistent hyperalgesia following exposure to inflammatory mediators (Huang et al., 2014) is increased in our study and in the transcriptomic study performed on motor neurons from human CHMP2B mutation carriers (Cox et al., 2010) . As disease progresses, down-regulation of voltage-gated potassium channels persists while deregulation of sodium channels disappears.
We also observed a deregulation of the Slc family of proteins involved in neurotransmitters re-uptake. This deregulation of the Slc family is also observed in motor neurons from human CHMP2B carriers (Cox et al., 2010) supporting the results obtained here with our model. In particular, Slc6a4 involved in the re-uptake of serotonin is decreased, and in the spinal cord serotonin (5-HT) increases motoneuron excitability. Interestingly, the serotonin receptor 3b
Htr3b is increased. In contrast, Slc6a5 encoding the glycine transporter 2 (GLYT2) is decreased. It has been shown that in spinal cord of SOD1 G93A ALS mice decreased GLYT2 expression is due to the degeneration of inhibitory interneurons possibly responsible for the hyperexcitability of motor neurons (Hossaini et al., 2011) . Further, Slc6a12 that codes GABA transporter involved in presynaptic GABA re-uptake is increased thereby possibly stopping GABA effect more rapidly. Moreover, Slc17a7 that encodes the vesicular glutamate transporter 1 is increased in Cox study and in our study (Cox et al., 2010) . Altogether one can hypothesizes that the convergence of these deregulations may drive a strong increase in neuronal excitability possibly initiating/participating to subsequent degeneration.
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Journal Pre-proof Finally, we also observed altered expression of genes related to extracellular matrix.
Deregulation of collagen and integrin expressing genes was also reported in the transcriptomic study performed in motor neurons from human CHMP2B carriers (Cox et al., 2010) . However, the consequences of these deregulations are not known and need to be further explored. Interestingly, part of the genes of the over-represented families at one stage are also deregulated at the other stages. In particular, for the immune system-inflammation and the lipid metabolism families, a deregulation of respectively 20% and 40% of the genes initially deregulated at the AS stage is seen suggesting an involvement of these genes in the processes activated at E stage. Understanding why these genes are deregulated at the AS and E stages could give us some clues on the role of these genes in the pathogenesis.
The comparison of the deregulated genes at the three studied stages of the disease allowed us to identify constantly deregulated genes. Among these genes 49% belong to families or pathways already found deregulated at, at least, one studied stage. Among the remaining genes, one can notice that four transcription factors are commonly up-regulated: Atf3 whose expression is increased in response to stress, Batf3 whose expression is involved in dendritic cell differentiation, Wisp2 that is up-regulated in ganglioside-deficient mice and though to have a neuroprotective function (Ohkawa et al., 2011) and Prrx2 a member of the paired family of homeobox proteins. The role of the others deregulated genes in the pathogenesis remains to be elucidated. Surprisingly, none of the pathways considered as responsible for the pathogenicity of CHMP2B mutants (i.e. endo-lysosomal pathway, autophagy) were found statistically overrepresented when analyzed with the chosen threshold. This unexpected result may reflect the fact that our analysis was performed on the whole lumbar spinal cord while CHMP2B intron5 expression was restricted to neurons. Nonetheless, considered individually, several genes related to these pathways (i.e. Rab, Atg, or cathepsins family members), were found deregulated strengthening the validity of our approach. If half of the identified genes common to the two ALS-causing mutants have already been associated with ALS or other neurodegenerative disorders (AnxA (Mishra et al., 2007) , Ugt8a (Sevastou et al., 2016 , Henriques et al., 2017 ), Atf3 (Malaspina et al., 2010 , Vlug et al., 2005 , Bcl3 (Ferry et al., 2014) , Crym (Daoud et al., 2011 , Fukada et al., 2007 , Runx1 (Patel et al., 2011) , Wisp2 (Sevastou et al., 2016) , Calca (Henriques et al., 2017) , Calcb, Cd44 (Matsumoto et al., 2012) , Clic1 (Novarino et al., 2004) , Hcar2 (Wakade et al., 2014) , Spp1 (Morisaki et al., 2016 , Yamamoto et al., 2017 , Lgals3 (Yan et al., 2016) , Hspb1 (Fukada et al., 2007 , Gorter et al., 2018 , Ylikallio et al., 2015 ) the remaining genes have not been described as modified or involved in neurodegenerative diseases . However, they are related to physiological functions (immune system, neuronal system, lipid metabolism etc…) known to be altered in neurodegenerative processes and in ALS in particular. Whether the change in expression of these genes is causative of the pathological process engaged by the two mutants or if it is a consequence has to be determined. Further work, including confirmation of changes at the protein level is now required in order to confirm whether they contribute to disease progression.
CONCLUSION
Our study is the first dynamic analysis of transcriptome in a CHMP2B intron5 mouse model, a model developing characteristic hallmarks of ALS/FTD. Our RNA-Seq analysis of lumbar spinal cord provides a snapshot of transcriptomic events characterizing the disease at three different time points giving us an access to the very early changes engaged before motor symptoms become apparent but also to the variations of gene expression profile when motor symptoms become detectable and then when mice are paralyzed. Our results highlight an early deregulation of immune system and lipid metabolism at asymptomatic stage although transgene expression is limited to neurons.
How mutant drives these deregulations remains an open question. Understanding the mechanisms underlying these alterations and determining whether they are protective or deleterious are of prime importance to delineate new therapeutic strategies for these diseases with not cure.
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We also show that appearance of motor symptoms correlate with the detectable deregulation of genes related to neuronal system and more specifically with genes involved in ions and neurotransmitters transport. These deregulations may underlie neuronal hyperexcitability that is thought to induce neuronal degeneration in ALS.
Finally the comparison of the gene expression signature of CHMP2B intron5 mice with those of SOD1 G86R mice at the symptomatic stage provides further insights into common underlying dysfunction of biological pathways, disrupted or disturbed in ALS.
It will now be interesting to test whether the genomic changes reported here have functional consequences at the level of the cognate proteins and then will then be reflected in changes in their activity. This will be particularly interesting for lipid metabolism pathway since their modification should be reflected by circulating metabolites (either in blood or CSF) and could then certainly serve as accessible biomarker for ALS, a presently unmet medical need.
In closing, our study provides a database for neuroscientists to explore potential candidate genes involved in the CHMP2B intron5 -based pathogenesis of ALS, and it may provide molecular clues to further understand the functional consequences that diseased neurons expressing CHMP2B mutant may have on their neighbor cells.
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